GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Other Income (Expense)

Paradigm Biopharmaceuticals (ASX:PAR) Other Income (Expense) : A$6.15 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Other Income (Expense)?

Paradigm Biopharmaceuticals's other income expense for the Paradigm Biopharmaceuticals's pretax income for the six months ended in Dec. 2023 was A$1.14 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$6.15 Mil.

Paradigm Biopharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Other Income (Expense) Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only 3.91 8.92 8.72 6.74 6.15

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.96 0.94 5.80 1.14 5.01

Paradigm Biopharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$6.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals  (ASX:PAR) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Paradigm Biopharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Other Income (Expense)
Comparable Companies
ASX:BOT ASX:RAC ASX:OPT ASX:PYC ASX:PIQ ASX:RCE ASX:BIT ASX:CU6 ASX:ALA ASX:DXB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PBIGF:USA
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Website
https://www.paradigmbiopharma.com
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.